These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16123370)

  • 1. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study.
    Lautamäki R; Airaksinen KE; Seppänen M; Toikka J; Luotolahti M; Ball E; Borra R; Härkönen R; Iozzo P; Stewart M; Knuuti J; Nuutila P
    Diabetes; 2005 Sep; 54(9):2787-94. PubMed ID: 16123370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
    Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
    Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
    Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
    Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin.
    Viljanen AP; Virtanen KA; Järvisalo MJ; Hällsten K; Parkkola R; Rönnemaa T; Lönnqvist F; Iozzo P; Ferrannini E; Nuutila P
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6523-8. PubMed ID: 16189256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
    Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
    Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
    Regensteiner JG; Bauer TA; Reusch JE
    Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
    Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
    Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.
    Natali A; Baldeweg S; Toschi E; Capaldo B; Barbaro D; Gastaldelli A; Yudkin JS; Ferrannini E
    Diabetes Care; 2004 Jun; 27(6):1349-57. PubMed ID: 15161787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
    Karlsson HK; Hällsten K; Björnholm M; Tsuchida H; Chibalin AV; Virtanen KA; Heinonen OJ; Lönnqvist F; Nuutila P; Zierath JR
    Diabetes; 2005 May; 54(5):1459-67. PubMed ID: 15855334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury.
    Yue TL; Bao W; Gu JL; Cui J; Tao L; Ma XL; Ohlstein EH; Jucker BM
    Diabetes; 2005 Feb; 54(2):554-62. PubMed ID: 15677515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.
    Borra R; Lautamäki R; Parkkola R; Komu M; Sijens PE; Hällsten K; Bergman J; Iozzo P; Nuutila P
    Metabolism; 2008 Oct; 57(10):1445-51. PubMed ID: 18803951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease.
    Søndergaard HM; Bøttcher M; Marie Madsen M; Schmitz O; Hansen SB; Nielsen TT; Bøtker HE
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4854-61. PubMed ID: 16984986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
    Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S
    Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease.
    Lautamäki R; Airaksinen KE; Seppänen M; Toikka J; Härkönen R; Luotolahti M; Borra R; Sundell J; Knuuti J; Nuutila P
    Diabetes; 2006 Feb; 55(2):511-6. PubMed ID: 16443788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.
    Naoumova RP; Kindler H; Leccisotti L; Mongillo M; Khan MT; Neuwirth C; Seed M; Holvoet P; Betteridge J; Camici PG
    J Am Coll Cardiol; 2007 Nov; 50(21):2051-8. PubMed ID: 18021872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.